Tag: big pharma

Corrupt Democrats Paid by Big Pharma Trying to Block Robert F. Kennedy’s Appointment

Corrupt Democrats Paid by Big Pharma Trying to Block Robert F. Kennedy’s Appointment

As I said, it is a fight to the death.

Years ago I thought Elizabeth Warren would be a good senator who would stand up for the people against the financial sector.  But I was wrong. Warren turned out to be just another unhinged Democrat.  Indeed, are there any Democrats who are not unhinged? 

Commentators are saying that the behavior of Democrats at Robert F. Kennedy’s confirmation hearing as Secretary of Health and Human Services was disgraceful.  Certainly it was.  But what it really demonstrates is what total shills Democrats are for Big Pharma.  

Warren’s outrage against Kennedy is explained by her annual payment of $821,941 in campaign contributions from Big Pharma whose vaccines have done extraordinary damage to people’s health.  Warren is the second highest paid Big Pharma senator after Bernie Sanders $1,417,811.

It is beyond question that the FDA, CDC, and NIH are revolving doors for Big Pharma.  Officials of these “regulatory” agencies give the go-ahead for dangerous drugs and vaccines such as the Covid vax.  Big Pharma makes billions of dollars killing people and destroying their health, and for their reward the “regulatory” officials are provided with million dollar jobs with Big Pharma.  The senate goes along with this for massive campaign contributions. This is just the beginning of the story.  Big Pharma’s research grants control medical school curriculums and the contents of medical journals.  Medical boards are also in Big Pharma’s pocket, and the corrupt boards yank the medical licenses of doctors who bring to light Big Pharma’s dangerous products.  It seems that the bulk of American mothers are brainwashed into believing their children will die unless vaccinated endlessly.  To their weak minds, “anti-vax” is a form of child abuse.

Keep reading

Emails reveal FDA refused to monitor select COVID-19 vaccine injuries from select vaccine manufacturers

In the first 18 months following the rollout of COVID-19 vaccines, the U.S. Food and Drug Administration (FDA) detected consistent safety alerts for the Janssen vaccine but largely overlooked similar risks for Pfizer and Moderna shots, according to newly released emails. These records, obtained through a Freedom of Information Act (FOIA) lawsuit by Children’s Health Defense (CHD), reveal a troubling pattern of oversight gaps in the federal government’s monitoring of vaccine injuries. Despite over 1.4 million adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), the FDA’s data analysis failed to flag widely recognized risks like myocarditis and pericarditis for mRNA vaccines. The revelations raise critical questions about the adequacy of the government’s safety monitoring and its commitment to transparency during the pandemic.

The FDA emails, posted on the agency’s website, detail weekly data mining of VAERS reports from January 12, 2021, to July 5, 2022. The analysis, known as Empirical Bayesian (EB) data mining, showed consistent alerts for serious adverse events linked to the Janssen vaccine, including deep vein thrombosis and death. However, the same analysis yielded almost no alerts for Pfizer and Moderna vaccines, even for well-documented risks like myocarditis and pericarditis.

For example, the FDA noted an alert for “death” associated with the Janssen vaccine on March 8, 2022, and in every subsequent email. In contrast, the agency flagged only a handful of administration-related issues for Pfizer and Moderna shots, such as “mechanical urticaria” and “exposure via breast milk.” This discrepancy is striking, given that VAERS received over 15,000 myocarditis reports and 10,000 pericarditis reports for mRNA vaccines during the same period.

Ray Flores, senior outside counsel to CHD, criticized the FDA’s approach, stating, “The emails are further evidence of the federal government’s failure to make good on its promises to use VAERS as an ‘early warning system’ to detect and act on risks associated with the new vaccines.”

Keep reading

RFK Jr. TORCHES Bernie Sanders For Taking Big Pharma Donations

The crowd went wild with applause on Thursday after Donald Trump Health and Human Services nominee Robert F. Kennedy Jr. slammed hypocrite Senator Bernie Sanders (I-Vt.) for taking millions of dollars from Big Pharma.

The moment came during day two of Kennedy’s Senate confirmation hearing, where he told Sanders, “By the way Bernie, the problem with corruption is not just in the federal agencies, it’s in Congress too. Almost all the members of this panel are accepting, including yourself, are accepting millions of dollars from the pharmaceutical industry.”

When the audience clapped in approval of RFK’s comment, Sanders angrily waved his hand in the air, saying, “Oh no! No, no, no, no… I ran for president like you. I got millions and millions of contributions. They did not come from the executives, not one nickel of PAC money from the pharmaceutical industry, they came from workers.”

Kennedy responded, “In 2020 you were the single largest receiver of pharmaceutical money… Bernie, you were the single largest accepter of pharmaceutical dollars. $1.5 million.”

“Yeah, out of $200 million,” Sanders answered.

During Wednesday’s confirmation hearing for Kennedy, the socialist senator launched into an unhinged tirade at Robert F. Kennedy Jr. regarding baby clothes that celebrate not taking vaccines.

Highlighting Kennedy’s former group Children’s Health Defense (CHD) advertised baby clothing that said “Unvaxxed Unafraid” and “No Vax, No Problem” on its website, Sanders shouted, “ARE YOU SUPPORTIVE OF THESE ONESIES?!”

Keep reading

Democrat Senator Triggered RFK Jr. Wants To Investigate Link Between SSRIs and Mass Shooters

Senator Tina Smith (D-Minn.) became upset that President Donald Trump’s Health and Human Services nominee Robert F. Kennedy Jr. once suggested antidepressant Big Pharma drugs may be connected to school shootings.

Citing 2023 and 2024 interviews featuring RFK during Wednesday’s Senate confirmation hearing, Smith read a quote where Kennedy once noted school children didn’t start shooting up schools until drugs such as Prozac were introduced to the masses.

She asked, “So, do you believe that antidepressants cause school shootings?”

Kennedy responded, “I don’t think anybody can answer that question, and I didn’t answer that question. I said it should be studied along with other potential culprits like social media…”

Senator Smith claimed, “The science shows that there is no link between school shootings and antidepressants, and in fact most school shooters were not even treated with antidepressants. And, of those that were, there was no evidence of association.”

“I don’t think you can say that Senator, because with HIPAA rules nobody knows,” RFK answered, referring to the fact that health privacy laws prevent the public from learning what medications school shooting suspects were prescribed.

The HHS nominee also pointed out SSRI drugs have suicidal and homicidal warnings on the labels.

Keep reading

Dem Sen. Elizabeth Warren Freaks Out Over Prospect Of RFK Jr. Suing Big Pharma Companies

Senator Elizabeth Warren (D-Mass.) lost her cool while questioning Donald Trump Health and Human Services appointee Robert F. Kennedy, Jr. during his Wednesday confirmation hearing.

At one point, the senator questioned whether Kennedy will use his position to benefit himself financially “down the line.”

“I’ll comply with all the ethical guidelines,” RFK tried answering before Warren interrupted, “That’s not the question!”

Kennedy told Warren, “Senator, you’re asking me to not sue vaccine, pharmaceutical companies,” causing her to shout, “No, I am not! My question is stop enriching yourself! No one should be fooled here.”

The Democrat politician continued berating RFK, claiming he will prevent parents from vaccinating their children, that “kids might die” while “Robert Kennedy can keep cashing in.”

Warren also asked Kennedy to promise he won’t take a job at a major pharmaceutical company after leaving his position as head of HHS.

Keep reading

Thiel-Linked HHS Nominee Threatens MAHA Ambitions with Biotech Stance

Late last November, President Donald Trump announced Jim O’Neill as his nominee for deputy secretary of Health and Human Services (HHS), where he would work under Robert F. Kennedy Jr., Trump’s pick for HHS secretary upon confirmation. As deputy secretary, O’Neill would essentially function as the Chief Operating Officer of the department, overseeing “the day-to-day operations of all sub-agencies” as well as leading “public health emergency preparedness,” i.e. the government’s policy responses to bio-terror events, pandemics, etc. In addition, O’Neill would “oversee the development and clearance of HHS regulations” and ostensibly be the main implementer of the “Make America Healthy Again” (MAHA) policy agenda.

Built on a promise to eliminate industry capture of public health regulatory agencies and curb the influence of Big Pharma and Big Food, Robert F. Kennedy Jr.’s MAHA movement played a crucial role in funneling would-be Kennedy voters into the Trump camp. MAHA, in essence, granted the Trump campaign a tinge of populist legitimacy among Covid era dissidents, which grew out of the shuttering of RFK Jr.’s independent presidential run.

However, O’Neill’s business connections, both past and present, as well as his previous statements on public health policy, strongly suggest that he is not only unlikely to implement the policies that MAHA-centric voters are expecting, but that he may in fact pursue an agenda that stands in direct conflict with the main tenets of the MAHA movement. Specifically, he advocates reforming the FDA to deregulate and accelerate the pathway from drug development to legalization. This would notably aid the biotech industry, which has long struggled to get its products approved outside of an “emergency”-based deregulatory paradigm.

When considering the investments and board positions that O’Neill himself has made and held in biotechnology companies, this would likely include mRNA products that Kennedy and other MAHA influencers have spent years criticizing since the Covid-19 pandemic — a clear contradiction between O’Neill’s views on public health, and those which the MAGA base were sold on the campaign trail.

Keep reading

Purdue Pharma and owners to pay $7.4 billion in settlement of lawsuits over the toll of OxyContin

Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription painkiller, the attorneys general from several states announced Thursday.

The deal, agreed to by Purdue Pharma, the Sackler family members who own the company and lawyers representing state and local governments and thousands of victims of the opioid crisis, replaces a previous settlement deal that was rejected last year by the U.S. Supreme Court.

In the new one, the Sacklers agreed to pay up to $6.5 billion and give up ownership of the company, which would pay nearly $900 million. The maximum contribution from family members is $500 million more than the previous deal.

It’s among the largest settlements reached over the past several years in a series of lawsuits by local, state, Native American tribal governments and others seeking to hold companies responsible for a deadly epidemic. Aside from the Purdue deal, others worth around $50 billion have been announced — and most of the money is required to be used to stem the crisis.

The deal still needs court approval, and some of the details are yet to be ironed out. An arm of the federal Department of Justice opposed the previous settlement, even after every state agreed, and took the battle to the U.S. Supreme Court. But under President Donald Trump, the federal government is not expected to oppose the new deal.

Keep reading

Pfizer Agrees to $60 Million Settlement in Kickback Scandal for Allegedly ‘Bribing’ Doctors to Promote Migraine Drug — Defrauding Medicare and Other Federal Health Programs

Big Pharma Pfizer has agreed to a hefty $59.7 million settlement to resolve allegations of a kickback scandal that has defrauded Medicare and other federal healthcare programs.

The scandal revolves around Biohaven Pharmaceutical, a company acquired by Pfizer in October 2022, which engaged in unethical practices to push prescriptions of its migraine medication, Nurtec ODT, also known as Rimegepant.

Whistleblower Patricia Frattasio, a former sales representative at Biohaven, played a crucial role in bringing these malpractices to light, leading to a qui tam lawsuit under the False Claims Act in 2021.

The U.S. Department of Justice disclosed that from March 2020 through September 2022, Biohaven manipulated the healthcare system by offering kickbacks—including speaker honoraria and lavish meals at upscale restaurants—to healthcare professionals.

Allegations include that Biohaven paid some healthcare providers over $100,000 to boost prescriptions of their migraine medication, Nurtec ODT, resulting in fraudulent claims to federal programs like Medicare and Medicaid.

This egregious scheme involved not just ordinary incentives, but also repeated, unnecessary educational programs that offered no real benefit to attendees, turning these events into mere facades for bribery.

This practice, aimed at increasing Nurtec ODT prescriptions, breached anti-kickback statutes designed to keep medical decisions free from financial influence.

Keep reading

Purdue Pharma, Sackler family owners agree to landmark $7.4B opioid settlement

Purdue Pharma and its Sackler family owners have reached a new $7.4 billion settlement to resolve thousands of lawsuits alleging that the pain medication Oxycontin caused a widespread opioid addiction crisis in the US, Texas attorney general Ken Paxton said Thursday.

The settlement was announced nearly seven months after the US Supreme Court upended the company’s previous attempt to resolve the lawsuits in a bankruptcy settlement that would have granted the Sacklers sweeping civil immunity from opioid lawsuits in exchange for a payment of up to $6 billion.

The Supreme Court ruled that the Sacklers, who did not file for bankruptcy themselves, were not entitled to legal protections meant to give bankrupt debtors a “fresh start.”

Under the new settlement, the Sacklers will pay $7.4 billion, without fully shutting off lawsuits from states, local governments, or individual victims of the opioid crisis. Those who do not wish to join the settlement are free to pursue lawsuits against the Sacklers, who have said they would vigorously defend themselves in court.

The deal was negotiated by 15 states, including New York, California, Connecticut, Oregon, Texas, Florida and West Virginia. The other states will be asked to sign on the settlement, which must be approved by a US bankruptcy judge before it becomes final.

Connecticut attorney General William Tong said that the settlement would help provide closure to victims of the opioid crisis.

“It’s not just about the money,” Tong said. “There is not enough money in the world to make it right.”

The latest settlement is meant to address a drug addiction crisis that has led to over 700,000 opioid overdose deaths in the United States over the past two decades.

Keep reading

J&J’s ketamine-derived nasal spray approved by FDA to treat depression

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression.

Spravato, approved as a standalone treatment, is “the first and only monotherapy for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,” the pharmaceutical giant said Tuesday. 

An estimated 21 million adults in the U.S. are living with major depressive disorder, one of the most common psychiatric disorders, but one-third of them will not respond to oral antidepressants alone, hindering their quality of life, according to Johnson & Johnson. 

“Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, healthcare providers have had few options to offer patients much-needed symptom improvement,” Bill Martin, global therapeutic area head of Neuroscience at Johnson & Johnson Innovative Medicine, said in a statement. 

Keep reading